跳至主要内容
临床试验/NCT00862667
NCT00862667已完成1 期

An Open Study To Estimate The Plasma Pharmacokinetics Of PF-00241939 Administered Via Oral Inhalation Using Dry Powder Inhalers.

Pfizer1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2009年5月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
Pfizer
入组人数
36
试验地点
1
主要终点
Plasma pharmacokinetic parameters: AUClast & Cmax.

研究概览

简要总结

The purpose of this study is to investigate the time course of PF-00241939 concentration in the blood following dosing by oral inhalation from dry powder inhalers.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
21 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male and/or female subjects between the ages of 21 and 55 years.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

排除标准

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
  • A positive urine drug screen.
  • History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males.
  • Pregnant or nursing females.

研究组 & 干预措施

Treatment A

Experimental

PF-00241939 300ug using Inhaler A

干预措施: Treatment A (Drug)

Treatment B

Active Comparator

PF-00241939 300ug using Inhaler B

干预措施: Treatment B (Drug)

Treatment C

Active Comparator

PF-00241939 300ug using Inhaler C

干预措施: Treatment C (Drug)

结局指标

主要结局

Plasma pharmacokinetic parameters: AUClast & Cmax.

时间窗: 48 hours

次要结局

  • Plasma pharmacokinetic parameters: AUC0-12, AUC0-24, AUCinf, Tmax and t½.(48 hours)

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验